“Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis”, Dermatol Reports, vol. 17, no. 1, Aug. 2024, doi: 10.4081/dr.2024.9999.